The document presents a comprehensive overview of polymorphism in pharmaceuticals, detailing types like enantiotropy and monotropy, identification methods including X-ray diffraction and FTIR, as well as the implications of polymorphism on drug solubility and bioavailability. It highlights the importance of understanding solid-state properties to avoid manufacturing challenges and ensure therapeutic efficacy. Case studies illustrate how variations in polymorphs can affect clinical outcomes, emphasizing the need for careful monitoring in drug development.
Related topics: